Ralexar Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Employees
- -
- Market Cap
- -
- Website
- http://www.ralexar.com
Study in Subjects With Moderate Atopic Dermatitis
Phase 2
- Conditions
- Atopic Dermatitis Eczema
- Interventions
- Drug: ALX-101 Gel 5%Drug: ALX-101 Gel Vehicle
- First Posted Date
- 2019-03-01
- Last Posted Date
- 2019-11-05
- Lead Sponsor
- Ralexar Therapeutics, Inc.
- Target Recruit Count
- 124
- Registration Number
- NCT03859986
- Locations
- 🇺🇸
Ralexar Investigational Site 5, Los Angeles, California, United States
🇺🇸Ralexar Investigational Site 10, Beverly Hills, California, United States
🇺🇸Ralexar Investigational Site 3, Aventura, Florida, United States
A Study in Subjects With Moderate Atopic Dermatitis
Phase 2
Completed
- Conditions
- Eczema, AtopicAtopic Dermatitis
- Interventions
- Drug: ALX-101 Gel 5% and ALX-101 Gel VehicleDrug: ALX-101 Gel 1.5% and ALX-101 Gel Vehicle
- First Posted Date
- 2017-06-05
- Last Posted Date
- 2018-10-25
- Lead Sponsor
- Ralexar Therapeutics, Inc.
- Target Recruit Count
- 209
- Registration Number
- NCT03175354
- Locations
- 🇺🇸
Ralexar Investigational Site 27, Santa Monica, California, United States
🇺🇸Ralexar Investigational Site 11, Warren, Michigan, United States
🇺🇸Ralexar Investigational Site 1, Miami, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath